Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin

European Journal of Pharmacology

Volumn 641, Issue 1, 2010, Pages 15-22

  Liu, Tingyan ^a   Peng, Huaguang ^a   Zhang, Meixia ^b   Deng, Yihui ^c   Wu, Zhenghu ^a  

^a HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Cisplatin; Cucurbitacin B; Hep 2

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CUCURBITACIN; CUCURBITACIN B; CYCLIN B1; PROTEIN BCL 2; STAT3 PROTEIN; UNCLASSIFIED DRUG; TRITERPENE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LARYNGEAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING; XENOGRAFT; ANIMAL; CHEMISTRY; DOWN REGULATION; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; LARYNX TUMOR; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLIN B1; DOWN-REGULATION; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LARYNGEAL NEOPLASMS; MICE; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953807862     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.04.062     Document Type: Article

References (45)

1. Aaronson D.S., Horvath C.M. A road map for those who don't know JAK-STAT. Science 2002, 296:1653-1655.
2. Argiris A., Karamouzis M.V., Raben D., Ferris R.L. Head and neck cancer. Lancet 2008, 371:1695-1709.
3. Ashimori N., Zeitlin B.D., Zhang Z., Warner K., Turkienicz I.M., Spalding A.C., Teknos T.N., Wang S., Nor J.E. TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Mol. Cancer Ther. 2009, 8:893-903.
4. Boehm A.L., Sen M., Seethala R., Gooding W.E., Freilino M., Wong S.M., Wang S., Johnson D.E., Grandis J.R. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol. Pharmacol. 2008, 73:1632-1642.
5. Bourhis J. New approaches to enhance chemotherapy in SCCHN. Ann. Oncol. 2005, 16(Suppl 6):vi20-vi24.
6. Chaigneau L., Guardiola E., N'guyen T., Dufresne A., Stein U., Villanueva C., Thiery-vuillemin A., Lorchel F., Pivot X. Induction chemotherapy in patients with head and neck cancer. Bull. Cancer 2006, 93:677-682.
7. Chanvorachote P., Pongrakhananon V., Wannachaiyasit S., Luanpitpong S., Rojanasakul Y., Nimmanntt U. Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation. Cancer Invest. 2009, 27:624-635.
8. Chen C.L., Cen L., Kohout J., Hutzen B., Chan C., Hsieh F.C., Loy A., Huang V., Cheng G., Lin J. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol. Cancer 2008, 7:78.
9. Chen C., Qiang S., Lou L., Zhao W. Cucurbitane-type triterpenoids from the stems of Cucumis melo. J. Nat. Prod. 2009, (Apr 6. Electronic publication ahead of print).
10. Clericuzio M., Mella M., Vita-Finzi P., Zema M., Vidari G. Cucurbitane triterpenoids from Leucopaxillus gentianeus. J. Nat. Prod. 2004, 67:1823-1828.
11. Deng J., Grande F., Neamati N. Small molecule inhibitors of Stat3 signaling pathway. Curr. Cancer Drug Targets 2007, 7:91-107.
12. Forastiere A.A. Chemotherapy in the treatment of locally advanced head and neck cancer. J. Surg. Oncol. 2008, 97:701-707.
13. Gao L.F., Wen L.J., Yu H., Zhang L., Meng Y., Shao Y.T., Xu D.Q., Zhao X.J. Knockdown of Stat3 expression using RNAi inhibits growth of laryngeal tumors in vivo. Acta Pharmacol. Sin. 2006, 27:347-352.
14. Germain D., Frank D.A. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin. Cancer Res. 2007, 13:5665-5669.
15. Guadagnolo B.A., Haddad R.I., Posner M.R., Weeks L., Wirth L.J., Norris C.M., Sullivan C.A., Goguen L., Busse P.M., Tishler R. Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer. Am. J. Clin. Oncol. 2005, 28:371-378.
16. Jayaprakasam B., Seeram N.P., Nair M.G. Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana. Cancer Lett. 2003, 189:11-16.
17. Jing N., Tweardy D.J. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005, 16:601-607.
18. Kaneko T., Zhang Z., Mantellini M.G., Karl E., Zeitlin B., Verhaegen M., Soengas M.S., Lingen M., Strieter R.M., Nunez G., Nor J.E. Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res. 2007, 67:9685-9693.
19. Klatka J., Paduch R., Pozarowski P., Pietruszewska W., Kupisz K., Trojanowski P., Rolinski J. Application of primary cell cultures of laryngeal carcinoma and laser scanning cytometry in the evaluation of tumor reactivity to cisplatinum. Folia Histochem. Cytobiol. 2008, 46:159-164.
20. Kongtun S., Jlratchariyakul W., Kummalue T., Tan-Ariya P., Kunnachak S., Frahm A.W. Cytotoxic properties of root extract and fruit juice of Trichosanthes cucumerina. Planta Med. 2009, 75:839-842.
21. Leeman R.J., Lui V.W., Grandis J.R. STAT3 as a therapeutic target in head and neck cancer. Expert. Opin. Biol. Ther. 2006, 6:231-241.
22. Liu T., Zhang M., Deng Y., Zhang H., Sun C., Yang X., Ji W. Effects of cucurbitacin B on cell proliferation and apoptosis in Hep-2 cells. Lin chuang er bi yan hou tou jing wai ke za zhi 2008, 22:403-407.
23. Liu T., Zhang M., Zhang H., Sun C., Deng Y. Inhibitory effects of cucurbitacin B on laryngeal squamous cell carcinoma. Eur. Arch. Otorhinolaryngol. 2008, 265:1225-1232.
24. Liu T., Zhnag M., Zhang H., Sun C., Yang X., Deng Y., Ji W. Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer. Eur. J. Pharmacol. 2008, 587:78-84.
25. Marioni G., Marchese-Ragona R., Cartei G., Marchese F., Staffieri A. Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat. Rev. 2006, 32:504-515.
26. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., Zhang S., Wang T., Sinibaldi D., Coppola D., Heller R., Ellis L.M., Karras J., Bromberg J., Pardoll D., Jove R., Yu H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21(13):2000-2008.
27. Posner M.R., Hershock D.M., Blajman C.R., Mickiewicz E., Winquist E., Gorbounova V., Tjulandin S., Shin D.M., Cullen K., Ervin T.J., Murphy B.A., Raez L.E., Cohen R.B., Spaulding M., Tishler R.B., Roth B., Viroglio Rdel C., Venkatesan V., Romanov I., Agarwala S., Harter K.W., Dugan M., Cmelak A., Markoe A.M., Read P.W., Steinbrenner L., Colevas A.D., Norris C.M., Haddad R.I. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med. 2007, 357:1705-1715.
28. Rapidis A.D., Trichas M., Stavrinidis E., Roupakia A., Ioannidou G., Kritsells G., Liossi P., Giannakouras G., Douzinas E.E., Katsilieris I. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up. Oral. Oncol. 2006, 42:675-684.
29. Reuter C.W., Morgan M.A., Eckardt A. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br. J. Cancer 2007, 96:408-416.
30. Scheper M.A., Nikitakis N.G., Chaisuparat R., Montaner S., Sauk J.J. Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma. Neoplasia 2007, 9:192-199.
31. Sun J., Blaskovich M.A., Jove R., Livingston S.K., Coppola D., Sebti S.M. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 2005, 24:3236-3245.
32. Tannin-Spitz T., Grossman S., Dovrat S., Gottlieb H.E., Bergman M. Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells. Biochem. Pharmacol. 2007, 73:56-67.
33. Tsao A.S., Garden A.S., Kies M.S., Morrison W., Feng L., Lee J.J., Khuri F., Zinner R., Myers J., Papadimitrakopoulou V., Lewin J., Clayman G.L., Ang K.K., Glisson B.S. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J. Clin. Oncol. 2006, 24:4163-4169.
34. Turkson J., Zhang S., Palmer J., Kay H., Stanko J., Mora L.B., Sebti S., Yu H., Jove R. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol. Cancer Ther. 2004, 3:1533-1542.
35. Turkson J., Zhang S., Mora L.B., Burns A., Sebti S., Jove R. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J. Biol. Chem. 2005, 280:32979-32988.
36. Vermorken J.B., Remenar E., Van Herpen C., Gorlla T., Mesia R., Degardin M., Stewart J.S., Jelic S., Betka J., Preiss J.H., VandenN Weyngaert D., Awada A., Cupissol D., Kienzer H.R., Rey A., Desaunois I., Bernier J., Lefebvre J.L. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N. Engl. J. Med. 2007, 57:1695-1704.
37. Vonminckwttz G. Docetaxel/anthracycline combinations for breast cancer treatment. Expert Opin. Pharmacother. 2007, 8:485-495.
38. Wakimoto N., Yin D., O'kelly J., Haritunians T., Karlan B., Said J., Xing H., Koeffler H.P. Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo. Cancer Sci. 2008, 99:1793-1797.
39. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005, 4:307-320.
40. Wang J.G., Li X.M., Chen Y.H., Lu X.Y. Molecular mechanisms involved in regulation of proliferation and apoptosis by STAT3 antisense oligonucleotide and chemotherapy in laryngeal cancer cells. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2007, 42:222-226.
41. Wang-Rodriguez J., Lopez J.P., Altuna X., Chu T.S., Weisman R.A., Ongkeko W.M. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro. Laryngoscope 2006, 116:1409-1416.
42. Wrighton K.H., Prele C.M., Sunters A., Yeudall W.A. Aberrant p53 alters DNA damage checkpoints in response to cisplatin: downregulation of CDK expression and activity. Int. J. Cancer 2004, 112:760-770.
43. Yde C.W., Issinger O.G. Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1. Int. J. Oncol. 2006, 29:1397-1404.
44. Yin D., Wakimoto N., Xing H., Lu D., Huynh T., Wang X., Black K.L., Koeffler H.P. cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. Int. J. Cancer 2008, 123:1364-1375.
45. Zhang M., Zhang H., Sun C., Shan X., Yang X., Li-Ling J., Deng Y. Targeted constitutive activation of signal transducer and activator of transcription 3 in human hepatocellular carcinoma cells by cucurbitacin B. Cancer Chemother. Pharmacol. 2009, 63:635-642.